Changes in the Global Pharmaceutical Industry and Growing Expectations for DDS technologies -from the standpoint of a business development service provider-

Abstract

The global pharmaceutical market was analyzed by monitoring companies’ financial results and aggregating product sales for each therapeutic categories. Cancer came to the top and autoimmune the second, while CVM dropped from the top to the third. Rapid growth was observed in the categories where pharmacological targets were newly identified for diseases with unmet medical needs. Launch of anti-PD1 products drastically changed treatment of lung cancer where antibody drugs were scarce. On the contrary, molecular-targeted drugs such as orally available CDK4/6 inhibitors changed breast cancer treatment where antibody drugs were dominant. Also in autoimmune diseases, new pharmacological targets such as IL-17A, IL-23, and integrin were identified. Oral JAK inhibitors to treat rheumatoid arthritis, and new targets such as CD-38, SLAMF7, and HDAC in multiple sclerosis were good examples of innovative pharmacology targets.